Conditions: Head and Neck Cancer
Keywords: Head and Neck Cancer Cetuximab Erbitux Paclitaxel Extreme Metastatic Recurrent
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 17
Healthy volunteers: no

Brief summary:
Treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) after progression to first line EXTREME-type treatment in patients undergoing maintenance treatment with cetuximab.

Detailed description:

Arms:
arm 1: Paclitaxel 80 mg/m2 may be infused, intravenously, every week. arm 2: Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.

Interventions: intervention 1: Paclitaxel intervention 2: Cetuximab + Paclitaxel
Intervention descriptions: intervention 1: Paclitaxel 80 mg/m2 may be infused, intravenously, every week. intervention 2: Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.

Protocol document: